Draft Rules Mandate Immediate Suspension Of Manufacturing Licences Under Drugs And Cosmetics Act

Notification/Circular No.: G.S.R. 956(E) dated October 28, 2026

Applicable Act/Rule: Drugs and Cosmetics Act, 1940; Drugs Rules, 1945

Applicable Section/Rule: Section 12(1) and Section 33(1); Rule 85 (insertion of sub-rules (2A) and (2AA) and amendment to sub-rule (3)); Rule 122O (insertion of sub-rules (1A) and (1AA) and amendment to sub-rule (2)); Form 13 (insertion)

Effective Period: November 04, 2026

Ministry of Health and Family Welfare (Department of Health and Family Welfare) has issued draft rules via G.S.R. 956(E) dated October 28, 2026, proposing amendments to the Drugs Rules, 1945 under Section 12(1) and Section 33(1) of the Drugs and Cosmetics Act, 1940. The draft addresses immediate suspension of manufacturing licences upon a Government Analyst’s adverse quality report and related procedural changes, and invites objections and suggestions.

Under the proposed insertion of Rule 85(2A), when the Central Licensing Approving Authority or the State Licensing Authority receives a certificate of test or analysis from a Government Analyst indicating that a drug is not of standard quality with respect to Assay, Dissolution, Related Substance, Impurity, or Sterility, the manufacturing licence for that drug shall be suspended immediately. The suspension will continue until the licensee conducts an effective root cause analysis and implements Corrective Action and Preventive Action (CAPA) to the satisfaction of the licensing authority. New Rule 85(2AA) provides that suspension may be revoked only after CAPA implementation has been duly verified by the licensing authority, and Rule 85(3) is amended to reference the new sub-rule (2A).

A corresponding framework is proposed in Rule 122O through new sub-rule (1A), requiring immediate suspension of a manufacturing licence upon a Government Analyst’s certificate that a drug is not of standard quality, with the suspension to remain in force until root cause analysis and CAPA are completed to the licensing authority’s satisfaction. New sub-rule (1AA) allows revocation only after due verification of CAPA implementation, and Rule 122O(2) is amended to refer to the new sub-rule (1A). The proviso authorises the Central Licensing Approving Authority to seek details of root cause analysis, CAPA, investigational report, and the final action taken by the State Licensing Authority to ensure compliance with the rule.

The draft further proposes an insertion in Form 13 to ensure that copies of the Government Analyst’s report are forwarded to the Drugs Controller General of India, the State/Union Territory Drug Control Authority under whose jurisdiction the manufacturing site is located, and the manufacturer and marketer named on the label. The draft rules will be taken into consideration after thirty days from the date the Gazette containing them is made available to the public. Objections and suggestions may be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall-C Wing, First Floor, Kartavya Bhawan-1, New Delhi, 110001, or emailed to drugsdiv-mohfw@gov.in within the specified period.

Link: https://egazette.gov.in/WriteReadData/2026/277656.pdf

Disclaimer: The information contained in this Article is intended solely for personal non-commercial use of the user who accepts full responsibility of its use. The information in the article is general in nature and should not be considered to be legal, tax, accounting, consulting or any other professional advice. We make no representation or warranty of any kind, express or implied regarding the accuracy, adequacy, reliability or completeness of any information on our page/article.

To stay updated Subscribe to our newsletter today

Explore other Legal updates on the Corplico and follow us on LinkedIn to stay updated

Post Views: 21

Schedule A Demo